Advertisement

Endocrine Hypertension

  • Perrin C. WhiteEmail author
Reference work entry

Abstract

Hypertension may be caused by abnormal synthesis of, or response to, various hormones. The proportion of pediatric hypertension cases resulting from such problems probably represents at most a few percent of cases overall, but a higher fraction of cases of severe hypertension, those occurring in the very young, or cases clustering in families. Most endocrine hypertension involves the adrenal gland and its hormones. The adrenal gland is composed of two endocrine tissues: the medulla (secreting catecholamines) and the cortex (synthesizing cortisol and aldosterone). Pheochromocytoma is mainly a disease of the adrenal medulla, although extramedullary sites may be involved. Many different diseases affecting the adrenal cortex can cause hypertension. These include hypertensive forms of congenital adrenal hyperplasia, primary aldosteronism due to hyperplasia of the zona glomerulosa or to adenomas, and Cushing’s syndrome (excessive glucocorticoid exposure) due to iatrogenic etiologies, to pituitary or adrenal adenomas, or to other tumors secreting excessive ACTH. Hypertension can also be caused by thyrotoxicosis due to Graves’ disease or to the thyrotoxic phase of Hashimoto’s thyroiditis. It is important to accurately diagnose these disorders because the associated hypertension requires, and usually responds well to, specific treatment of the underlying hormonal abnormality.

Keywords

ACTH Adrenal Aldosterone Catecholamines Congenital adrenal hyperplasia Cortisol Cushing’s syndrome Graves’ disease Thyrotoxicosis Thyroxine 

References

  1. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metabol 88(12):5593–5602Google Scholar
  2. Assie G, Libe R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, Barreau O, Lefevre L, Sibony M, Guignat L, Rodriguez S, Perlemoine K, Rene-Corail F, Letourneur F, Trabulsi B, Poussier A, Chabbert-Buffet N, Borson-Chazot F, Groussin L, Bertagna X, Stratakis CA, Ragazzon B, Bertherat J (2013) ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N Engl J Med 369(22):2105–2114PubMedPubMedCentralGoogle Scholar
  3. Auchus RJ (2001) The genetics, pathophysiology, and management of human deficiencies of P450c17. [Review] [77 refs]. Endocrinol Metab Clin North Am 30(1):101–119PubMedGoogle Scholar
  4. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C (2011) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metabol 96(3):717–725Google Scholar
  5. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21(6):593–646Google Scholar
  6. Barker FG, Klibanski A, Swearingen B (2003) Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metabol 88(10):4709–4719Google Scholar
  7. Bassett MH, Suzuki T, Sasano H, White PC, Rainey WE (2004) The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production. Mol Endocrinol 18(2):279–290PubMedGoogle Scholar
  8. Batista DL, Riar J, Keil M, Stratakis CA (2007) Diagnostic tests for children who are referred for the investigation of Cushing’s syndrome. Pediatrics 120(3):e575–e586PubMedGoogle Scholar
  9. Beuschlein F, Fassnacht M, Assie G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T, Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Reincke M, Bertherat J, Strom TM, Allolio B (2014) Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. N Engl J Med 370(11):1019–1028PubMedPubMedCentralGoogle Scholar
  10. Brenta G, Danzi S, Klein I (2007) Potential therapeutic applications of thyroid hormone analogs. Nat Clin Pract Endocrinol Metab 3(9):632–640PubMedGoogle Scholar
  11. Charmandari E, Kino T, Ichijo T, Chrousos GP (2008) Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. J Clin Endocrinol Metabol 93(5):1563–1572Google Scholar
  12. Charmandari E, Kino T, Chrousos GP (2013) Primary generalized familial and sporadic glucocorticoid resistance (Chrousos syndrome) and hypersensitivity. Endocr Dev 24:67–85PubMedPubMedCentralGoogle Scholar
  13. Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39(6):775–783PubMedPubMedCentralGoogle Scholar
  14. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Akerstrom G, Wang W, Carling T, Lifton RP (2011) K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331(6018):768–772PubMedPubMedCentralGoogle Scholar
  15. Cicala MV, Mantero F (2010) Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology 92(Suppl 1):44–49. Epub;%2010 Sep 10, 44–49PubMedGoogle Scholar
  16. Clark AJ, Metherell LA (2006) Mechanisms of disease: the adrenocorticotropin receptor and disease. Nat Clin Pract Endocrinol Metab 2(5):282–290PubMedGoogle Scholar
  17. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM (2012) A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366(10):914–924PubMedGoogle Scholar
  18. Condon JC, Pezzi V, Drummond BM, Yin S, Rainey WE (2002) Calmodulin-dependent kinase I regulates adrenal cell expression of aldosterone synthase. Endocrinology 143(9):3651–3657PubMedGoogle Scholar
  19. Curnow KM, Tusie-Luna MT, Pascoe L, Natarajan R, Gu JL, Nadler JL, White PC (1991) The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocrinol 5:1513–1522PubMedGoogle Scholar
  20. Curnow KM, Slutsker L, Vitek J, Cole T, Speiser PW, New MI, White PC, Pascoe L (1993) Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. Proc Natl Acad Sci U S A 90:4552–4556PubMedPubMedCentralGoogle Scholar
  21. Dannenberg H, van Nederveen FH, Abbou M, Verhofstad AA, Komminoth P, de Krijger RR, Dinjens WN (2005) Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD. J Clin Oncol 23(9):1894–1901PubMedGoogle Scholar
  22. Derlin T, Busch JD, Wisotzki C, Schoennagel BP, Bannas P, Papp L, Klutmann S, Habermann CR (2013) Intraindividual comparison of 123I-mIBG SPECT/MRI, 123I-mIBG SPECT/CT, and MRI for the detection of adrenal pheochromocytoma in patients with elevated urine or plasma catecholamines. Clin Nucl Med 38(1):e1–6PubMedGoogle Scholar
  23. Donckier JE, Michel L (2010) Phaeochromocytoma: state-of-the-art. Acta Chir Belg 110(2):140–148PubMedGoogle Scholar
  24. Dumitrescu AM, Refetoff S (2007) Novel biological and clinical aspects of thyroid hormone metabolism. Endocr Dev 10:127–139PubMedGoogle Scholar
  25. Eisenhofer G, Timmers HJ, Lenders JW, Bornstein SR, Tiebel O, Mannelli M, King KS, Vocke CD, Linehan WM, Bratslavsky G, Pacak K (2011) Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. J Clin Endocrinol Metabol 96(2):375–384Google Scholar
  26. Eisenhofer G, Lattke P, Herberg M, Siegert G, Qin N, Darr R, Hoyer J, Villringer A, Prejbisz A, Januszewicz A, Remaley A, Martucci V, Pacak K, Ross HA, Sweep FC, Lenders JW (2013) Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Ann Clin Biochem 50(Pt 1):62–69PubMedPubMedCentralGoogle Scholar
  27. Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, Brauckhoff M, Mussig K, Muresan M, Schaffler A, Reisch N, Schott M, Fassnacht M, Opocher G, Klose S, Fottner C, Forrer F, Plockinger U, Petersenn S, Zabolotny D, Kollukch O, Yaremchuk S, Januszewicz A, Walz MK, Eng C, Neumann HP (2009) Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res 15(20):6378–6385PubMedGoogle Scholar
  28. Fishbein L, Nathanson KL (2012) Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet 205(1–2):1–11PubMedPubMedCentralGoogle Scholar
  29. Funder J (2001) Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 28(12):1002–1006PubMedGoogle Scholar
  30. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 93(9):3266–3281Google Scholar
  31. Gershengorn MC, Neumann S (2012) Update in TSH receptor agonists and antagonists. J Clin Endocrinol Metab 97:4287–4292PubMedPubMedCentralGoogle Scholar
  32. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S (2007) Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 112(8):417–428Google Scholar
  33. Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ, Stein E, Levine E, Delimpasi G, Hsiao HP, Keil M, Heyerdahl S, Matyakhina L, Libe R, Fratticci A, Kirschner LS, Cramer K, Gaillard RC, Bertagna X, Carney JA, Bertherat J, Bossis I, Stratakis CA (2006) A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 38(7):794–800PubMedGoogle Scholar
  34. Horvath A, Giatzakis C, Tsang K, Greene E, Osorio P, Boikos S, Libe R, Patronas Y, Robinson-White A, Remmers E, Bertherat J, Nesterova M, Stratakis CA (2008) A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. Eur J Hum Genet 16(10):1245–1253PubMedPubMedCentralGoogle Scholar
  35. Ilias I, Divgi C, Pacak K (2011) Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer. Semin Nucl Med 41(5):364–368PubMedPubMedCentralGoogle Scholar
  36. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA (2000) Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26(1):89–92PubMedGoogle Scholar
  37. Kleinau G, Krause G (2009) Thyrotropin and homologous glycoprotein hormone receptors: structural and functional aspects of extracellular signaling mechanisms. Endocr Rev 30(2):133–151PubMedGoogle Scholar
  38. Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing’s syndrome. Lancet 386(9996):913–927PubMedGoogle Scholar
  39. Lee JA, Grumbach MM, Clark OH (2007) The optimal treatment for pediatric Graves’ disease is surgery. J Clin Endocrinol Metabol 92(3):801–803Google Scholar
  40. Li JS, Flynn JT, Portman R, Davis I, Ogawa M, Shi H, Pressler ML (2010) The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr 157(2):282–287PubMedGoogle Scholar
  41. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM (1992) A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355:262–265PubMedGoogle Scholar
  42. Lodish M, Stratakis CA (2016) A genetic and molecular update on adrenocortical causes of Cushing’s syndrome. Nat Rev Endocrinol 12(5):255–262PubMedGoogle Scholar
  43. Lodish M, Dunn SV, Sinaii N, Keil MF, Stratakis CA (2012) Recovery of the hypothalamic-pituitary-adrenal axis in children and adolescents after surgical cure of Cushing’s disease. J Clin Endocrinol Metabol 97(5):1483–1491Google Scholar
  44. Luiz HV, Tanchee MJ, Pavlatou MG, Yu R, Nambuba J, Wolf K, Prodanov T, Wesley R, Adams K, Fojo T, Pacak K (2016) Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. Clin Endocrinol (Oxf) 85(1):62–69Google Scholar
  45. Martinez-Aguayo A, Aglony M, Campino C, Garcia H, Bancalari R, Bolte L, Avalos C, Loureiro C, Carvajal CA, Avila A, Perez V, Inostroza A, Fardella CE (2010) Aldosterone, plasma renin activity, and aldosterone/renin ratio in a normotensive healthy pediatric population. Hypertension 56(3):391–396PubMedGoogle Scholar
  46. Miller WL, Auchus RJ (2011) The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 32(1):81–151PubMedGoogle Scholar
  47. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC (1995) Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 10:394–399PubMedGoogle Scholar
  48. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A (2011) Guidelines for the diagnosis and treatment of primary aldosteronism – the Japan Endocrine Society 2009. Endocr J 58(9):711–721PubMedGoogle Scholar
  49. Nogueira EF, Rainey WE (2010) Regulation of aldosterone synthase by activator transcription factor/cAMP response element-binding protein family members. Endocrinology 151(3):1060–1070PubMedPubMedCentralGoogle Scholar
  50. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM, Tischler AS (2007) Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 3(2):92–102PubMedGoogle Scholar
  51. Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI, White PC (1992) Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci U S A 89:8327–8331PubMedPubMedCentralGoogle Scholar
  52. Rivkees SA, Dinauer C (2007) An optimal treatment for pediatric Graves’ disease is radioiodine. J Clin Endocrinol Metabol 92(3):797–800Google Scholar
  53. Rivkees SA, Mattison DR (2009) Ending propylthiouracil-induced liver failure in children. N Engl J Med 360(15):1574–1575PubMedGoogle Scholar
  54. Santos IN, Spadari-Bratfisch RC (2006) Stress and cardiac beta adrenoceptors. Stress 9(2):69–84PubMedGoogle Scholar
  55. Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley FL, Farhi A, Wang WH, Lifton RP (2012) Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A 109(7):2533–2538PubMedPubMedCentralGoogle Scholar
  56. Schovanek J, Martucci V, Wesley R, Fojo T, Del RJ, Huynh T, Adams K, Kebebew E, Frysak Z, Stratakis CA, Pacak K (2014) The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. BMC Cancer 14:523PubMedPubMedCentralGoogle Scholar
  57. Silva JE, Bianco SD (2008) Thyroid-adrenergic interactions: physiological and clinical implications. Thyroid 18(2):157–165PubMedGoogle Scholar
  58. Soundararajan R, Pearce D, Hughey RP, Kleyman TR (2010) Role of epithelial sodium channels and their regulators in hypertension. J Biol Chem 285(40):30363–30369PubMedPubMedCentralGoogle Scholar
  59. Steichen O, Zinzindohoue F, Plouin PF, Amar L (2012) Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. Horm Metab Res 44(3):221–227PubMedGoogle Scholar
  60. Stocco DM (2001) StAR protein and the regulation of steroid hormone biosynthesis. [Review] [162 refs]. Annu Rev Physiol 63:193–213PubMedGoogle Scholar
  61. Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD (2012) Factors affecting the aldosterone/renin ratio. Horm Metab Res 44(3):170–176PubMedGoogle Scholar
  62. Tomaschitz A, Pilz S, Ritz E, Obermayer-Pietsch B, Pieber TR (2010) Aldosterone and arterial hypertension. Nat Rev Endocrinol 6(2):83–93PubMedGoogle Scholar
  63. Tomlinson JW, Stewart PM (2005) Mechanisms of disease: selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat Clin Pract Endocrinol Metab 1(2):92–99. Available from: PM:16929377PubMedGoogle Scholar
  64. Turkova H, Prodanov T, Maly M, Martucci V, Adams K, Widimsky J Jr, Chen CC, Ling A, Kebebew E, Stratakis CA, Fojo T, Pacak K (2016) Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma/paraganglioma: an National Institutes Of Health study. Endocr Pract 22(3):302–314PubMedGoogle Scholar
  65. Vaidya A, Hamrahian AH, Auchus RJ (2015) Genetics of primary aldosteronism. Endocr Pract 21(4):400–405PubMedPubMedCentralGoogle Scholar
  66. Waguespack SG, Rich T, Grubbs E, Ying AK, Perrier ND, Ayala-Ramirez M, Jimenez C (2010) A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metabol 95(5):2023–2037Google Scholar
  67. Weingarten TN, Cata JP, O’Hara JF, Prybilla DJ, Pike TL, Thompson GB, Grant CS, Warner DO, Bravo E, Sprung J (2010) Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma. Urology 76(2):508–511PubMedGoogle Scholar
  68. Weise M, Merke DP, Pacak K, Walther MM, Eisenhofer G (2002) Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metabol 87(5):1955–1960Google Scholar
  69. White PC (2001) Steroid 11 beta-hydroxylase deficiency and related disorders. [Review] [60 refs]. Endocrinol Metab Clin North Am 30(1):61–79PubMedGoogle Scholar
  70. White PC, Mune T, Agarwal AK (1997) 11b-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18:135–156PubMedGoogle Scholar
  71. Wilson C (2012) Pituitary function: Cushing’s disease – long-term outcome after transsphenoidal surgery. Nat Rev Endocrinol 8(4):194PubMedGoogle Scholar
  72. Yang S, Zhang L (2004) Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol 2(1):1–12PubMedGoogle Scholar
  73. Yang M, Soga T, Pollard PJ (2013) Oncometabolites: linking altered metabolism with cancer. J Clin Investig 123(9):3652–3658PubMedGoogle Scholar
  74. Zinnamosca L, Petramala L, Cotesta D, Marinelli C, Schina M, Cianci R, Giustini S, Sciomer S, Anastasi E, Calvieri S, De TG, Letizia C (2011) Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. Arch Dermatol Res 303(5):317–325PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Division of Pediatric Endocrinology, Department of PediatricsUT Southwestern Medical Center and Children’s Medical CenterDallasUSA

Section editors and affiliations

  • Joseph T. Flynn
    • 1
    • 2
  1. 1.Division of NephrologySeattle Children’s HospitalSeattleUSA
  2. 2.Department of PediatricsUniversity of Washington School of MedicineSeattleUSA

Personalised recommendations